• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Ventyx Biosciences Inc.

    4/8/25 3:14:41 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VTYX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Ventyx Biosciences, Inc.

    (Name of Issuer)


    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)


    92332V107

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    92332V107


    1Names of Reporting Persons

    Sio Capital Management, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,582,655.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,582,655.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,582,655.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.63 %
    12Type of Reporting Person (See Instructions)

    IA

    Comment for Type of Reporting Person:  1 As of March 31, 2025, Sio Capital Management, LLC beneficially owned 2,582,655 shares of Common Stock with shared voting power and shared dispositive power. 2 Based on 71,130,054 shares of common stock outstanding as of February 24, 2025, as reported in the Issuer's Form 10-K filed with the SEC on February 27, 2025.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Ventyx Biosciences, Inc.
    (b)Address of issuer's principal executive offices:

    12790 El Camino Real, Suite 200, San Diego, CALIFORNIA, 92130
    Item 2. 
    (a)Name of person filing:

    This Statement is filed on behalf of Sio Capital Management, LLC (the "Reporting Person" or "Sio") Sio is a registered investment adviser to certain affiliated funds that directly hold the shares of Common Stock to which this statement relates for the benefit of their respective investors, and in such capacity Sio has voting and dispositive power over such shares.
    (b)Address or principal business office or, if none, residence:

    600 Third Avenue, 2nd Floor New York, New York 10016
    (c)Citizenship:

    Sio is a Delaware limited liability company.
    (d)Title of class of securities:

    Common Stock, $0.0001 par value per share
    (e)CUSIP No.:

    92332V107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    2,582,655
    (b)Percent of class:

    3.63%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    2,582,655 - Refer to footnote 3

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    2,582,655 - Refer to footnote 3 3 Sio and Sio GP, LLC (the "GP") act as investment advisor and general partner, respectively, to various clients that are the record owners of the Common Stock reported on this Schedule 13G. Because Sio's investment discretion with respect to such clients is subject to oversight by the GP, the GP may be deemed to be the beneficial owner of the Common Stock of the Issuer owned by such clients. In addition, both Sio and the GP are controlled by Michael Castor. As such, he may be deemed to control the voting and dispositive decisions with respect to, and therefore be the beneficial owner of, the shares of Common Stock reported on this Schedule 13G. Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission by the GP or Michael Castor that such person is the beneficial owner of any of the equity securities referred to herein for purposes of Section 13(d) of the Exchange Act, or for any other purpose, and such beneficial ownership is expressly disclaimed.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Sio Capital Management, LLC
     
    Signature:/s/ Jin W. Lee
    Name/Title:Chief Compliance Officer
    Date:04/04/2025
    Get the next $VTYX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VTYX

    DatePrice TargetRatingAnalyst
    3/12/2024$12.00Perform → Outperform
    Oppenheimer
    3/12/2024$7.00 → $16.00Equal Weight → Overweight
    Wells Fargo
    11/7/2023$46.00 → $6.00Overweight → Equal-Weight
    Morgan Stanley
    11/7/2023Outperform → Perform
    Oppenheimer
    11/7/2023Buy → Neutral
    H.C. Wainwright
    11/7/2023$6.00Buy → Hold
    Stifel
    11/7/2023$77.00 → $8.00Overweight → Equal Weight
    Wells Fargo
    6/14/2023$63.00Outperform
    Credit Suisse
    More analyst ratings

    $VTYX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ventyx Biosciences upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded Ventyx Biosciences from Perform to Outperform and set a new price target of $12.00

      3/12/24 7:35:44 AM ET
      $VTYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ventyx Biosciences upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded Ventyx Biosciences from Equal Weight to Overweight and set a new price target of $16.00 from $7.00 previously

      3/12/24 7:35:12 AM ET
      $VTYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ventyx Biosciences downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Ventyx Biosciences from Overweight to Equal-Weight and set a new price target of $6.00 from $46.00 previously

      11/7/23 11:05:19 AM ET
      $VTYX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTYX
    Leadership Updates

    Live Leadership Updates

    See more
    • Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists

      Appointment of seven recognized experts is validating for Ventyx's NLRP3 Program--AD/PD™ 2025 provides helpful insights on potential next steps in Parkinson's disease SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx", "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases, today announced the appointment of seven additional internationally-recognized scientists and clinicians to its Scientific Advisory Board (SAB): Mo Lamkanfi, PhD, Luke O'Neill, PhD, Ted Dawson, MD, PhD, Martin Pomper, MD, PhD, Antonio Abbate, MD, PhD, Paul Cremer, MD

      4/1/25 7:00:00 AM ET
      $VTYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress

      A Phase 2 obesity and cardiometabolic trial of VTX3232 and a Phase 2a trial of VTX3232 in patients with Parkinson's disease are both expected to initiate in H2 2024 A Phase 2 trial of VTX2735 in recurrent pericarditis is expected to initiate in H2 2024 Mark Forman, MD, PhD will join Ventyx as Chief Medical Officer effective August 12, 2024 Cash, cash equivalents and marketable securities of $279.7 million as of June 30, 2024 are expected to fund planned operations into at least the second half of 2026 SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapie

      8/8/24 4:01:00 PM ET
      $VTYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer

      SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX), ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced the appointment of industry veteran Matthew Moore as Chief Operating Officer. "I am excited to welcome Matt to the Ventyx leadership team," said Raju Mohan, Chief Executive Officer. "He brings a wealth of expertise to Ventyx from his multiple decades in the biopharma industry. In his role as COO, Matt will play an important role in driving corporate operations, business development and strategy." "I am excited to

      5/16/24 8:00:00 AM ET
      $VTYX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTYX
    Financials

    Live finance-specific insights

    See more
    • Ventyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Progress

      Phase 2a trials of CNS-Penetrant NLRP3 Inhibitor VTX3232 to initiate in H2 2024 in patients with early Parkinson's disease and in participants with obesity with certain additional cardiovascular risk factors Cash, cash equivalents and marketable securities of $302.6 million as of March 31, 2024 are expected to fund planned operations into at least the second half of 2026 Ventyx to host conference call and webcast today at 4:30PM ET SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medi

      5/9/24 4:01:00 PM ET
      $VTYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024

      SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX), ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that it will report financial results for the first quarter ended March 31, 2024 after market close on May 9, 2024. Company management will host a conference call and webcast beginning at 4:30 p.m. ET/ 1:30 p.m. PT that day to discuss the financial results and highlight recent pipeline and business progress. To participate in the conference call, please dial (800) 343-4849 (U.S.) or (203) 518-9848 (international)

      5/2/24 4:05:00 PM ET
      $VTYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event

      VTX3232 was well-tolerated in the Phase 1 trial with robust target coverage achieved in both plasma and CSF; Ventyx is planning to initiate Phase 2a trials in Parkinson's disease and obesity in H2 2024 Topline Phase 2 data for VTX2735 in CAPS patients establish clinical proof of concept; Ventyx is planning to evaluate VTX2735 in cardiovascular diseases Early Phase 2 open-label extension data continue to support the clinical profile of VTX002 in ulcerative colitis; Ventyx is planning to seek a partner or other nondilutive financing for pivotal Phase 3 trial Based on pipeline reprioritization and recent PIPE financing, Ventyx expects its current cash, cash equivalents and marketable securit

      3/11/24 7:00:00 AM ET
      $VTYX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTYX
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Ventyx Biosciences Inc.

      SCHEDULE 13G - Ventyx Biosciences, Inc. (0001851194) (Subject)

      5/30/25 7:01:07 PM ET
      $VTYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Ventyx Biosciences Inc.

      SCHEDULE 13G/A - Ventyx Biosciences, Inc. (0001851194) (Subject)

      5/15/25 5:29:54 PM ET
      $VTYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Ventyx Biosciences Inc.

      SCHEDULE 13G/A - Ventyx Biosciences, Inc. (0001851194) (Subject)

      5/15/25 1:10:00 PM ET
      $VTYX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTYX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Ventyx Biosciences Inc.

      SC 13G/A - Ventyx Biosciences, Inc. (0001851194) (Subject)

      11/14/24 7:54:08 PM ET
      $VTYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Ventyx Biosciences Inc.

      SC 13G/A - Ventyx Biosciences, Inc. (0001851194) (Subject)

      11/14/24 3:06:49 PM ET
      $VTYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Ventyx Biosciences Inc.

      SC 13G/A - Ventyx Biosciences, Inc. (0001851194) (Subject)

      11/14/24 8:57:39 AM ET
      $VTYX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTYX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference

      SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx", "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that Company executives will participate in a fireside chat at the upcoming Jefferies Global Healthcare Conference. Event: Jefferies Global Healthcare Conference, New York Fireside ChatDate: Thursday, June 5, 2025 Time: 12:50-1:20 PM ET A webcast of the event will be available in the Investors and News section of the Ventyx website at www.ventyxbio.com. A webcast replay will also be available on this web

      5/28/25 8:00:00 AM ET
      $VTYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress

      Topline data from multiple Phase 2 studies expected throughout 2025 • Q2 readout from VTX3232 study in patients with early Parkinson's disease • H2 readout from VTX2735 study in patients with recurrent pericarditis • H2 readout from VTX3232 study in participants with obesity and cardiometabolic risk factors Cash, cash equivalents and marketable securities balance of $228.8M as of March 31, 2025 expected to fund planned operations into at least H2 2026 SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx", "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflamm

      5/8/25 4:01:00 PM ET
      $VTYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists

      Appointment of seven recognized experts is validating for Ventyx's NLRP3 Program--AD/PD™ 2025 provides helpful insights on potential next steps in Parkinson's disease SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx", "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases, today announced the appointment of seven additional internationally-recognized scientists and clinicians to its Scientific Advisory Board (SAB): Mo Lamkanfi, PhD, Luke O'Neill, PhD, Ted Dawson, MD, PhD, Martin Pomper, MD, PhD, Antonio Abbate, MD, PhD, Paul Cremer, MD

      4/1/25 7:00:00 AM ET
      $VTYX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTYX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Gujrathi Sheila bought $300,573 worth of shares (130,000 units at $2.31) (SEC Form 4)

      4 - Ventyx Biosciences, Inc. (0001851194) (Issuer)

      12/26/24 8:05:18 PM ET
      $VTYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO AND PRESIDENT Mohan Raju bought $959,889 worth of shares (500,000 units at $1.92), increasing direct ownership by 30% to 2,175,028 units (SEC Form 4)

      4 - Ventyx Biosciences, Inc. (0001851194) (Issuer)

      11/25/24 9:07:34 PM ET
      $VTYX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTYX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Senior VP, Finance Gonzales Roy was granted 1,750 shares, increasing direct ownership by 97% to 3,546 units (SEC Form 4)

      4 - Ventyx Biosciences, Inc. (0001851194) (Issuer)

      5/16/25 6:41:55 PM ET
      $VTYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Forman Mark S was granted 3,000 shares (SEC Form 4)

      4 - Ventyx Biosciences, Inc. (0001851194) (Issuer)

      5/16/25 6:40:27 PM ET
      $VTYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF SCIENTIFIC OFFICER Nuss John sold $2,019 worth of shares (1,887 units at $1.07), decreasing direct ownership by 0.40% to 467,226 units (SEC Form 4)

      4 - Ventyx Biosciences, Inc. (0001851194) (Issuer)

      4/3/25 4:21:34 PM ET
      $VTYX
      Biotechnology: Pharmaceutical Preparations
      Health Care